As the medical and scientific community embrace psychedelic treatment, and as regulators clear these treatments, a need has arisen to take prospective patients through the entire process so that they make informed decisions and know who to turn to for help. Osmind, a mental health startup, has risen to the occasion to provide the needed support.
Osmind aims at creating a community for people seeking psychedelic treatments which have FDA-approval. Currently, only ketamine has this regulatory approval, but industry insiders expect similar approval to be given to psilocybin and MDMA. Osmind is building an app as well as an online platform through which patients can learn about all available psychedelic treatments. The Osmind community is especially geared towards patients who have mental health conditions that are resistant to the existing treatments.
Osmind is the brainchild of Jimmy Qian and Lucia Huang. The two met at Stanford University during a healthcare IT class. Qian was a student at the medical school at Stanford while Huang was at the business school. The shared IT class therefore gave them an opportunity to meet and realize that they both had a passion for mental health.
Jimmy Qian reveals that as a medical student, he had seen the data on what toll mental health conditions are taking on the U.S. population, and what he read about ketamine blow his mind away.
Similarly, Lucia Huang is emotionally invested in their project because she has firsthand experience of what depression and other mental health conditions have done to family members, friends and college students.
Consequently, the pair is excited about what psychedelics can do for millions of people, and they would like to do their part to make safe and responsible access to psychedelic treatments easy for those who need it.
Their online community is already active and it is a place where people can go when they need support, and those who can offer this needed support also get the chance to help others. Already, information verified by medical doctors is available to those who join the online community.
This community is particularly important during this COVID-19 pandemic since human contact is minimal and yet that is what mental health patients need the most. The platform provides information about the different licensed clinics where patients can access psychedelic treatments. The startup also avails information about the ways in which services are provided at those treatment centers.
For example, community members can know whether a given facility provides e-prescriptions or prescriptions are provided only after an in-person visit to the facility. Ultimately, the startup intends to help advance research into different life-changing medicines, especially psychedelics.
The work of Osmind ties in very well with what other entities, such as Compass Pathways and Salvation Botanicals, are doing to advance the field of psychedelics. The future can only get brighter for people suffering from mental health disorders!
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.